Medical/Pharmaceuticals
Major strategic engagement program to create greater awareness of fertility health issues in the APAC region
SINGAPORE, May 12, 2025 /PRNewswire/ -- The Asia Pacific Initiative on Reproduction (ASPIRE) – the peak body harnessing expertise in assisted conception throughout the region – will embark on a major public education and awareness program on fertility health. It is also working to broaden its ...
2025-05-12 05:23
2533
Mediso completes Cryo-Free MRI Magnet Tech Transfer from SSI
BUDAPEST, Hungary, May 9, 2025 /PRNewswire/ -- Mediso is pleased to announce the successful completion of the first phase of a strategic technology transfer agreement with Superconducting Systems Inc. (SSI), a fully owned subsidiary of IMRIS. This agreement marks a significant milestone in Mediso...
2025-05-09 21:00
3446
Asia's First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring
A landmark study recently published in March 2025 by JCO Oncology Advances,
demonstrates the potential ofK-TRACKTM
2025-05-09 14:01
2864
THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA
BANGKOK, May 9, 2025 /PRNewswire/ -- A professor from Chulalongkorn University's
Faculty of Science
2025-05-09 10:00
2629
DNV recognized as a Notified Body for Certification under In Vitro Diagnostic Regulation (IVDR)
OSLO, Norway, May 8, 2025 /PRNewswire/ -- DNV, the independent assurance and risk management provider, has been recognized by the European Commission as a notified body for the certification of devices under the European Union's In Vitro Diagnostic Regulation (IVDR). The designation increases cap...
2025-05-08 22:38
3350
Colorcon and ASHA Cellulose Announce New Partnership to Support the Development & Manufacture of Barrier Membrane Formulations for the Pharmaceutical and Nutraceutical Industries
HARLEYSVILLE, Pa. and MUMBAI, India, May 8, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the healthcare industry, today announced an exclusive partnership with ASHA Cellulose, ...
2025-05-08 17:00
2412
Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers
HERLEV, Denmark, May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease r...
2025-05-08 16:49
2775
QDX Congratulates Co-Founder and Head of Research A/Prof. Giuseppe Barca on Receiving the 2025 Dirac Medal
SINGAPORE, May 8, 2025 /PRNewswire/ -- QDX proudly congratulates its Co-Founder and Head of Research,A/Prof. Giuseppe Barca, on being awarded the 2025 Dirac Medal, the highest international honour for early-career researchers in theoretical and computational chemistry. Presented by the World Ass...
2025-05-08 16:10
2552
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
SINGAPORE, May 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase 1 trial evaluating SCG101, autologous HBV-specific...
2025-05-08 09:00
2524
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
* End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179naïve participants, strengthening the case for a novel enrichmen...
2025-05-08 08:10
2860
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published inThyroid, the official journal of the ...
2025-05-08 05:00
2396
Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing
New company unveiled at the annual ISCT conference in New Orleans combines two tenured and innovative CDMOs with a testing powerhouse PHILADELPHIA, May 7, 2025 /PRNewswire/ -- Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S...
2025-05-07 20:12
2383
The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China
* The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease was significantly greater than that in the placebo group, of which the difference was statistically si...
2025-05-07 14:19
3810
Britishpedia Honours Family Podiatry Centre Founder, Mark Reyneker, As a Success Icon
SINGAPORE, May 7, 2025 /PRNewswire/ -- Mark Reyneker, founder of the Family Podiatry Centre, will be featured in the 7th Edition of Britishpedia's "Successful People in Malaysia and Singapore." He has been recognised for his significant contributions to podiatry in Singapore and Malaysia, highlig...
2025-05-07 10:00
1806
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
* AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint resea...
2025-05-07 08:03
2108
Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2025-05-07 08:00
3842
Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression
SHANGHAI, May 7, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the supplemental New Drug Applica...
2025-05-07 07:30
2657
FutureLink Boston 2025 Reinforces TraceLink's Leadership in Supply Chain Orchestration and Innovation
BOSTON, May 7, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, successfully hosted FutureLink Boston 2025, bringing together more than 150 attendees ranging across senior executives, industry experts, and supply chain tech...
2025-05-07 00:39
2321
Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World
SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Plasmidsaurus, the company that sequences while you sleep, today announced the opening of its tenth global sequencing lab, located inSingapore's vibrant biomedical hub. The new site dramatically shortens turnaround times for ...
2025-05-06 23:56
2694
Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT PLEASANT, S...
2025-05-06 22:12
2992
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 299 media titles]
2026-02-10 13:31Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 299 media titles]
2026-02-09 10:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Angel Yeast Indonesia Project: Strengthening Foundations through Technical Training and Building Consensus through Cultural Exchange
2026-02-07 09:31
9738
NYSE Content Update: Children's Food Brand Once Upon a Farm to Open for Trade
2026-02-07 01:09
7819
Doorzo Ends 2025 with Its Strongest Year, Reaching a Decade Total of ¥80 Billion and Reinforcing Its Vision as "Your Gateway to Japan"
2026-02-07 07:00
7135
/C O R R E C T I O N -- Fairland Group - iGarden/
2026-02-08 17:31
6871
